极光激酶A（AURKA）抑制模拟了BRCA缺陷状态。 - Suppr

Suppr

超能文献

AURKA inhibition mimics BRCAness.

作者信息

Hirst Jeff, Godwin Andrew K

机构信息

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66201, USA.

University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS 66201, USA.

出版信息

Aging (Albany NY). 2017 Sep 11;9(9):1945-1946. doi: 10.18632/aging.101291.

DOI:10.18632/aging.101291

PMID:28898201

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5636662/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31d/5636662/6cb75508db6c/aging-09-1945-g001.jpg

相似文献

AURKA inhibition mimics BRCAness.极光激酶A（AURKA）抑制模拟了BRCA缺陷状态。

Aging (Albany NY). 2017 Sep 11;9(9):1945-1946. doi: 10.18632/aging.101291.

A Novel Mechanism to Induce BRCAness in Cancer Cells.一种诱导癌细胞出现 BRCA 样特征的新机制

Cancer Res. 2020 Jul 15;80(14):2977-2978. doi: 10.1158/0008-5472.CAN-20-1451.

Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.聚（ADP - 核糖）聚合酶抑制剂治疗乳腺癌易感基因1/2突变癌症中DNA双链断裂修复途径的相互作用

Cancer Sci. 2018 Apr;109(4):893-899. doi: 10.1111/cas.13530. Epub 2018 Mar 6.

Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.通过替代性双链断裂修复、复制应激和有丝分裂异常来塑造 BRCA 基因突变景观。

Nucleic Acids Res. 2021 May 7;49(8):4239-4257. doi: 10.1093/nar/gkab151.

PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.PARP 介导的修复、同源重组和单链缺口的备用非同源末端连接样修复。

DNA Repair (Amst). 2013 Jul;12(7):529-34. doi: 10.1016/j.dnarep.2013.04.004. Epub 2013 May 16.

DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.“BRCAness”小鼠模型中 DNA 修复和细胞周期检验点缺陷部分通过 53BP1 缺失得到挽救。

Cell Cycle. 2018;17(7):881-891. doi: 10.1080/15384101.2018.1456295. Epub 2018 May 15.

Defining and Modulating 'BRCAness'.定义和调节“BRCA 样特征”。

Trends Cell Biol. 2019 Sep;29(9):740-751. doi: 10.1016/j.tcb.2019.06.005. Epub 2019 Jul 27.

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.PARP 和 BRCA 合成致死的潜在机制：澄清误解。

Mol Oncol. 2011 Aug;5(4):387-93. doi: 10.1016/j.molonc.2011.07.001. Epub 2011 Jul 22.

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.聚（ADP-核糖）聚合酶抑制剂能引发 BRCA 基因合成致死，并靶向聚 ADP 核糖聚合酶抑制剂耐药性。

Nat Commun. 2021 Jun 17;12(1):3636. doi: 10.1038/s41467-021-23463-8.

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.同源重组修复途径的基因表达谱分析表明奥拉帕利在体外恶性胸膜间皮瘤治疗中的敏感性。

BMC Cancer. 2019 Jan 30;19(1):108. doi: 10.1186/s12885-019-5314-0.

引用本文的文献

Dual targeting of Aurora Kinase A and poly (ADP-ribose) polymerase as a therapeutic option for patients with ovarian cancer: preclinical evaluations.靶向极光激酶A和聚（ADP - 核糖）聚合酶作为卵巢癌患者的一种治疗选择：临床前评估

J Cancer Res Clin Oncol. 2025 Mar 26;151(3):124. doi: 10.1007/s00432-025-06152-7.

A Bayesian active learning platform for scalable combination drug screens.用于可扩展联合药物筛选的贝叶斯主动学习平台。

Nat Commun. 2025 Jan 2;16(1):156. doi: 10.1038/s41467-024-55287-7.

ReCorDE: a framework for identifying drug classes targeting shared vulnerabilities with applications to synergistic drug discovery.ReCorDE：一个用于识别针对共同脆弱性的药物类别并应用于协同药物发现的框架。

Front Oncol. 2024 May 31;14:1343091. doi: 10.3389/fonc.2024.1343091. eCollection 2024.

Aurora Kinase A inhibition enhances DNA damage and tumor cell death with I-MIBG therapy in high-risk neuroblastoma.在高危神经母细胞瘤中，极光激酶A抑制与I-间碘苄胍疗法联合可增强DNA损伤和肿瘤细胞死亡。

EJNMMI Res. 2024 Jun 13;14(1):54. doi: 10.1186/s13550-024-01112-7.

Screening and expression verification of key genes in cutaneous squamous cell carcinoma.皮肤鳞状细胞癌关键基因的筛选与表达验证

Transl Cancer Res. 2022 Jun;11(6):1730-1739. doi: 10.21037/tcr-22-1267.

Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.沉默 Aurora-kinase-A（AURKA）通过抑制β-连环蛋白和 RAS-细胞外信号调节蛋白激酶（ERK1/2）通路增强弥漫性大 B 细胞淋巴瘤细胞对环磷酰胺、多柔比星、长春新碱和泼尼松（CHOP）的敏感性。

Bioengineered. 2021 Dec;12(1):8296-8308. doi: 10.1080/21655979.2021.1985346.

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer.靶向极光激酶A（AAK）治疗铂耐药高级别浆液性卵巢癌

Front Oncol. 2020 Aug 19;10:1354. doi: 10.3389/fonc.2020.01354. eCollection 2020.

Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.调节PARP活性用于靶向癌症治疗的治疗策略和生物标志物

Cancers (Basel). 2020 Apr 14;12(4):972. doi: 10.3390/cancers12040972.

本文引用的文献

Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.极光激酶A调节卵巢癌细胞中的非同源末端连接和聚（ADP-核糖）聚合酶功能。

Oncotarget. 2017 Jul 5;8(31):50376-50392. doi: 10.18632/oncotarget.18970. eCollection 2017 Aug 1.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.尼拉帕利维持治疗铂敏感复发性卵巢癌。

N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7.

The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy.极光激酶A/B与乳腺癌易感基因1/2之间的负性相互作用通过对细胞周期进程、胞质分裂和四倍体的不同调控来控制癌细胞生长和肿瘤发生。

Mol Cancer. 2014 Apr 28;13:94. doi: 10.1186/1476-4598-13-94.

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.极光激酶 A 介导上皮性卵巢癌细胞迁移和黏附。

Oncogene. 2014 Jan 30;33(5):539-49. doi: 10.1038/onc.2012.632. Epub 2013 Jan 21.

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.MLN8237（alisertib）的 II 期研究，一种研究性的 Aurora A 激酶抑制剂，用于治疗铂类耐药或铂类难治的上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。

Gynecol Oncol. 2012 Oct;127(1):63-9. doi: 10.1016/j.ygyno.2012.06.040. Epub 2012 Jul 5.

Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.双重抑制 SRC 和 Aurora 激酶可导致有丝分裂后附着缺陷和细胞死亡。

Oncogene. 2012 Mar 8;31(10):1217-27. doi: 10.1038/onc.2011.314. Epub 2011 Jul 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验